Egetis Therapeutics AB (publ) (STO: EGTX)

Sweden flag Sweden · Delayed Price · Currency is SEK
5.80
-0.09 (-1.53%)
Aug 30, 2024, 5:29 PM CET
21.34%
Market Cap 1.70B
Revenue (ttm) 70.80M
Net Income (ttm) -319.40M
Shares Out 292.57M
EPS (ttm) -1.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 298,901
Open 5.90
Previous Close 5.89
Day's Range 5.77 - 5.92
52-Week Range 3.83 - 9.30
Beta 1.44
Analysts n/a
Price Target n/a
Earnings Date Nov 8, 2024

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (p... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 34
Stock Exchange Nasdaq Stockholm
Ticker Symbol EGTX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.